Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-08-20
2010-10-05
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S224000, C544S182000
Reexamination Certificate
active
07807674
ABSTRACT:
Provided herein are compounds of the formula (I):as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto.
REFERENCES:
patent: 4582842 (1986-04-01), Cragoe, Jr. et al.
patent: 5284971 (1994-02-01), Walker et al.
patent: 188351 (1991-03-01), None
patent: 728482 (1996-08-01), None
patent: WO 9639388 (1996-12-01), None
patent: WO 9702023 (1997-01-01), None
patent: WO 9857919 (1998-12-01), None
patent: WO 9900353 (1999-01-01), None
patent: WO 00/17204 (2000-03-01), None
patent: WO 2005051298 (2005-06-01), None
Sircar, et al., J. Med. Chem., 1989, 32(2), 342-50.
Paul M. Yen Physiological reviews, vol. 81(3): pp. 1097-1126 (2001).
M.A. Lazar Endocrine Reviews, vol. 14: pp. 348-399 (1993).
Abel et. al. J. Clin. Invest., vol. 104: pp. 291-300 (1999).
B. Gloss et. al. Endocrinology, vol. 142: pp. 544-550 (2001).
C. Johansson et. al. Am. J. Physiol., vol. 275: pp. R640-R646 (1998).
Paul Webb Expert Opin. Investig. Drugs, vol. 13(5): pp. 489-500 (2004).
Eugene Morkin et. al. Journal of Molecular and Cellular Cardiology, vol. 37: pp. 1137-1146 (2004).
J.J. Abrams et. al. J. Lipid Res., vol. 22: pp. 323-38 (1981).
M. Aviram et. al. Clin. Biochem., vol. 15: pp. 62-66 (1982).
Gene C. Ness et. al. Biochemical Pharmacology, vol. 56: pp. 121-129 (1998).
G.J. Grover et. al. Endocrinology, vol. 145: pp. 1656-1661 (2004).
G.J. Grover et. al. Proc. Natl. Acad. Sci. USA, vol. 100: pp. 10067-10072 (2003).
de Bruin et. al. J. Clin. Endo. Metab., vol. 76: pp. 121-126 (1993).
A.H. Underwood et al. Nature, vol. 324: pp. 425-429 (1986).
Malm Johan Current Pharmaceutical Design, vol. 10(28): pp. 3525-3532 (2004).
Expert Opin. Ther. Patents, vol. 14: pp. 1169-1183 (2004).
Thomas S. Scalan Current Opinion in Drug Discovery & Development, vol. 4(5): pp. 614-622 (2001).
Teruomi et. al. Agricultural and Biological Chemistry, vol. 38(6):1169-76 (1974).
P.D. Leeson et. al. J. Med. Chem. vol. 32: pp. 320-326 (1989).
H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 196.
H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at p. 1456-1457.
H. Ansel et. al., Pharmaceutical Dosage Forms and Drug Delivery Systems (6th Ed. 1995) at pp. 108-109.
Krogsgaard-Larsen, et. al., Textbook of Drug Design and Development (2d Ed. 1996) at pp. 152-191.
Gardner, P. D., et. al inJ. Amer. Chem. Soc., 1959, 81, 3364.
Organic Preparations and Procedures International, 1988, 20(1-2), 117-121.
J. Chem. Soc. Perkin Trans. 1: Org. and Bioorg. Chem., 1988, 12, 3103-3111.
J. Amer. Chem. Soc., 1989, 111(24), 8912-8914.
Anelli, P.L., et. al.,J. Org. Chem., 1987, 52(12), 2559-2562.
Maeda, R., et. al.,Chem. Pharm. Bull., 1983, 31(10), 3424-3445.
Bowden, K. et. al.,J. Chem. Soc., 1946, 39-45.
Sellstedt. J.H., et. al.,J. Med. Chem., 1975, 18(9), 926-933.
Minisci, F., et. al.,J. Org. Chem., 1995, 60, 5430-5433.
Carroll, R.D., et. al.,J. Med. Chem., 1983, 26, 96-100.
J. Med. Chem., 1989, 32(10), 2381-2388.
Hauser, C. R., et. al.,J. Amer. Chem. Soc., 1945, 67, 409-412.
Doyle, M.P., et. al., J. Org. Chem., 1977, 42(14), 2426-2431.
Takatori, K., et. al.,Tetrahedron, 1998, 54, 15861-15869.
Yoon, N.M., et. al.,J. Org. Chem., 1985, 50, 2443-2450.
Lan, Aj. J. Y., et. al.,J. Amer. Chem. Soc., 1987, 109, 2738-2745.
Law, H., et. al.J. Med. Chem., 1998, 41, 2243-2251.
Wenner, O., Org. Synth.; Coll. vol. IV, 1963, 760.
Buu-Hoy, P., et. al.,J. Org. Chem., 1953, 18, 649-652.
Miyashita, M., et. al.,J. Org. Chem., 1977, 42, 3882-3774.
Sotelo, E., et. al.,Synth. Commun., 2002, 32(11), 1675-1680.
Chaudhary, S.K., et. al.,Tet. Lett., 1979, 20(2), 99-102.
D.M. Springer, et. al.,Bioorg Med. Chem., 2003, 11, 265-279.
Org. Syn. Coll. vol. 2, 1943, 471.
Vera, L.M.S., et. al.,Farmaco, 2003, 58(12), 1283-1288.
J. Org. Chem., 1998, 63, 5658-5661.
Can. J. Chem. 2001, 79(5-6), 752-759.
J. Het. Chem., 1994, 31(6), 1439-43.
Gattermann, L. (1914),Die Praxis des organischen Chemikers(12), 228.
Haynes Nancy Ellen
Kertesz Denis J.
Pietranico-Cole Sherrie Lynn
Qian Yimin
Scott Nathan Robert
Hoffmann-La Roche Inc.
Jaisle Cecilia M
Johnston George W.
Megerditchian Samuel H.
Tramaloni Dennis P.
LandOfFree
Thyroid hormone analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thyroid hormone analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thyroid hormone analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4151856